How it works
Survodutide acts as a dual GLP-1 and GCGR receptor agonist. It reduces appetite, delays gastric emptying, increases energy expenditure, and enhances insulin secretion. These effects result in weight reduction and improved glucose control.
Recommended for:
Clinical evidence:
Administered subcutaneously under medical supervision. The dosage is tailored individually depending on patient condition and treatment goals.
Adverse reactions:









